NEW YORK, NY / ACCESSWIRE / November 7, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Capital One Financial Corporation (NYSE:COF)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/capital-one-financial-corporation-loss-submission-form?prid=4249&wire=1
Lead Plaintiff Deadline: December 2, 2019
Class Period: February 2, 2018 to July 29, 2019
Allegations against COF include that: (1) the Company did not maintain robust information security protections, and its protection did not shield personal information against security breaches; (2) such deficiencies heightened the Company's exposure to a cyber-attack; and (3) as a result, Capital One's public statements were materially false and misleading at all relevant times.
MacroGenics, Inc. (NASDAQGS:MGNX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/macrogenics-inc-loss-submission-form?prid=4249&wire=1
Lead Plaintiff Deadline: November 12, 2019
Class Period: February 6, 2019 to June 3, 2019
Allegations against MGNX include that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.
Covetrus, Inc. (NASDAQ:CVET)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/covetrus-inc-loss-submission-form?prid=4249&wire=1
Lead Plaintiff Deadline: November 29, 2019
Class Period: February 8, 2019 to August 12, 2019
Allegations against CVET include that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein's Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company's separation from Henry Schein.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong